Press Releases

Oct 4 07	Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Aug 1 07	Aegerion Pharmaceuticals, Inc. Hires Vice President, General Counsel And Secretary
Mar 29 07	Former Pfizer & Esperion Pharmaceuticals Regulatory Executive to Lead Aegerion’s Regulatory Efforts.
Jan 10 07	New England Journal of Medicine Reports Aegerion's Lead Compound Reduces LDL by 51% in Patients With a Severe Form of Hypercholesterolemia
Nov 15 06	Aegerion Study Shows Combination Treatment With Aegr-733 And Zetia® Reduces LDL Levels By 35% After Four Weeks Of Therapy
Oct 6 06	Aegerion Pharmaceuticals Enters into Cross License Agreement
Sep 25 06	Aegerion Pharmaceuticals Inc. Hires Vice President of Business Development
Jun 13 06	Aegerion Pharmaceuticals Completes $22.5 Million Series A Round; Financing Will Fund Additional Development Efforts in Dyslipidemia

Events
American Heart Association Scientific Sessions 2006 November 12 - 15 , 2006 Chicago, Illinois Presenting: November 15, 2006/9:00 AM - 12:00 pm McCormick Place E351 C.E. Unterberg Towbin Life Sciences Conference October 30 - 31, 2006 The Palace Hotel, New York Will Lewis Presenting: October 31, 2006

Events